Filing Details

Accession Number:
0001104659-19-066292
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-21 17:02:48
Reporting Period:
2019-11-19
Accepted Time:
2019-11-21 17:02:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1384859 Peter Kolchinsky 200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-11-19 397,183 $23.92 2,059,486 No 4 S Indirect See Note
Common Stock Disposition 2019-11-20 265,505 $22.93 1,793,981 No 4 S Indirect See Note
Common Stock Disposition 2019-11-21 351,505 $22.98 1,442,476 No 4 S Indirect See Note
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Note
No 4 S Indirect See Note
No 4 S Indirect See Note
Footnotes
  1. The securities sold include (a) 337,605 shares of Common Stock by RA Capital Healthcare Fund, L.P. (the "Fund") and (b) 59,578 shares of Common Stock by a separately managed account (the "Account").
  2. This transaction was executed in multiple trades at prices ranging from $23.84 to $23.9794; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  3. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP") of which Dr. Peter Kolchinsky is a managing member. Dr. Kolchinsky disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a)(2) under the Exchange Act except to the extent of his pecuniary interest therein.
  4. The securities sold include (a) 225,680 shares of Common Stock by the Fund and (b) 39,825 shares of Common Stock by the Account.
  5. This transaction was executed in multiple trades at prices ranging from $22.7951 to $22.9756.
  6. The securities sold include (a) 298,779 shares of Common Stock by the Fund and (b) 52,726 shares of Common Stock by the Account.
  7. This transaction was executed in multiple trades at prices ranging from $22.5711 to $23.0607.
  8. Following the reported transactions, the Fund held 1,296,617 shares and the Account held 145,859 shares.